Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 May;165(4):504-9.
doi: 10.1111/bjh.12778. Epub 2014 Mar 3.

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

Anjali S Advani  1 , Shannon McDonough, Steven Coutre, Brent Wood, Jerald Radich, Martha Mims, Margaret O'Donnell, Stephanie Elkins, Michael Becker, Megan Othus, Frederick R Appelbaum
Affiliations
Clinical Trial

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

Anjali S Advani et al. Br J Haematol. 2014 May.

Abstract

Precursor B-acute lymphoblastic leukaemias (pre-B ALLs) comprise the majority of ALLs and virtually all blasts express CD22 in the cytoplasm and on the cell surface. In the present study (Southwestern Oncology Group S0910), we evaluated the addition of epratuzumab, a humanized monoclonal antibody against CD22, to the combination of clofarabine and cytarabine in adults with relapsed/refractory pre-B ALL. The response rate [complete remission and complete remission with incomplete count recovery] was 52%, significantly higher than our previous trial with clofarabine/cytarabine alone, where the response rate was 17%. This result is encouraging and suggests a potential benefit to adding epratuzumab to chemotherapy for ALL; however, a randomized trial will be needed to answer this question.

Keywords: CD22; Treatment; acute lymphocytic leukaemia; epratuzumab; relapse.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest:

AS Advani has received some funding and honoraria from Genzyme

References

    1. Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre S, Stuart RK, Mims MP, Stiff PJ, Appelbaum FR. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol. 2010;151(5):430–434. - PMC - PubMed
    1. Boue DR, LeBien TW. Expression and structure of CD22 in acute leukaemia. Blood. 1988;71:480–486. - PubMed
    1. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM, Goldstone AH. Outcome of 609 adults after relapse of acute lymphoblastic leukaemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–950. - PubMed
    1. Herrara L, Farah RA, Pellegrini VA. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukaemia cells in vitro. Leukaemia. 2000;14:853–858. - PubMed
    1. Hoelzer D. High-dose chemotherapy in adult acute lymphoblastic leukaemia. Semin Hematol. 1991;28 (3 Suppl 4):84–89. - PubMed

Publication types

MeSH terms